In addition, inhibition of NUAK1 with the small-molecule HTH-01-015 was PTEN-SSL in a wide range of cell lines, confirming the broad-spectrum PTEN-SSL activity of NUAK1. Our findings support the introduction of therapies targeting NUAK1, including inhibitors such as HTH-01-015, for treatment of PTEN-deficient breast cancers. The gene discussed is PTEN; the disease is breast carcinoma.